58 research outputs found
Prevalence of severe esophagitis in Spain. Results of the PRESS study (Prevalence and Risk factors for Esophagitis in Spain: A cross-sectional study)
Background The current prevalence of esophagitis in southern Europe is unknown. In addition, the risk factors for reflux esophagitis are not fully understood. Objective The objective of this article is to assess the prevalence and risk factors for esophagitis in Spain. Methods A prospective, observational, cross-sectional, multicenter study (PRESS study) was conducted among 31 gastrointestinal endoscopy units throughout Spain. A total of 1361 patients undergoing upper gastrointestinal endoscopy were enrolled. Sociodemographic, clinical and treatment data were recorded. Results A total of 95% of patients were Caucasian and 52% were male (mean age: 5317 years). The most frequent symptoms prompting endoscopy were heartburn (40%), regurgitation (26%) and dysphagia (15%). Fifty-four percent of patients undergoing endoscopy were receiving proton pump inhibitor (PPI) treatment. Esophagitis (mainly mild-moderate) was present in 154 (12.4%) patients. The severe form was recorded in only 11 (0.8%) patients. Multivariate analysis results indicated that the likelihood of esophagitis was higher in men (OR=1.91, 95% CI=1.31-2.78), in patients with high GERD-Q scores (OR=1.256, 95% CI=1.176-1.343), weight increase (OR=1.014, 95% CI=1.003-1.025) and high alcohol consumption (OR=2.49, 95% CI=1.16-5.36). Conclusion Severe esophagitis is a rare finding in the Spanish population. Male gender, high GERD-Q score, weight increase and high alcohol consumption are main risk factors for its appearance
Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts
Gastrointestinal (GI) bleeding is associated with considerable morbidity and
mortality. Red blood cell (RBC) transfusion has long been the cornerstone
of treatment for anemia due to GI bleeding. However, blood is not devoid
of potential adverse effects, and it is also a precious resource, with limited
supplies in blood banks. Nowadays, all patients should benefit from a
patient blood management (PBM) program that aims to minimize blood loss,
optimize hematopoiesis (mainly by using iron replacement therapy), maximize
tolerance of anemia, and avoid unnecessary transfusions. Integration of PBM
into healthcare management reduces patient mortality and morbidity and
supports a restrictive RBC transfusion approach by reducing transfusion rates.
The European Commission has outlined strategies to support hospitals with
the implementation of PBM, but it is vital that these initiatives are translated
into clinical practice. To help optimize management of anemia and iron
deficiency in adults with acute or chronic GI bleeding, we developed a
protocol under the auspices of the Spanish Association of Gastroenterology,
in collaboration with healthcare professionals from 16 hospitals across
Spain, including expert advice from different specialties involved in PBM
strategies, such as internal medicine physicians, intensive care specialists,
and hematologists. Recommendations include how to identify patients who
have anemia (or iron deficiency) requiring oral/intravenous iron replacement
therapy and/or RBC transfusion (using a restrictive approach to transfusion),
and transfusing RBC units 1 unit at a time, with assessment of patients after
each given unit (i.e., âdonât give two without reviewâ). The advantages and
limitations of oral versus intravenous iron and guidance on the safe and
effective use of intravenous iron are also described. Implementation of a PBM
strategy and clinical decision-making support, including early treatment of
anemia with iron supplementation in patients with GI bleeding, may improve
patient outcomes and lower hospital costs
A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis.
The genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated. To increase the current knowledge on the genetic component of this vasculitis we performed the first genome-wide association study (GWAS) on this condition. 308 IgA vasculitis patients and 1,018 healthy controls from Spain were genotyped by Illumina HumanCore BeadChips. Imputation of GWAS data was performed using the 1000 Genomes Project Phase III dataset as reference panel. After quality control filters and GWAS imputation, 285 patients and 1,006 controls remained in the datasets and were included in further analysis. Additionally, the human leukocyte antigen (HLA) region was comprehensively studied by imputing classical alleles and polymorphic amino acid positions. A linkage disequilibrium block of polymorphisms located in the HLA class II region surpassed the genome-wide level of significance (ORâ=â0.56, 95% CIâ=â0.46-0.68). Although no polymorphic amino acid positions were associated at the genome-wide level of significance, P-values of potential relevance were observed for the positions 13 and 11 of HLA-DRB1 (Pâ=â6.67E-05, Pâ=â1.88E-05, respectively). Outside the HLA, potential associations were detected, but none of them were close to the statistical significance. In conclusion, our study suggests that IgA vasculitis is an archetypal HLA class II disease
Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis
Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.Acknowledgements: We are indebted to the patients and healthy controls for their essential collaboration to this study. We also thank the National DNA Bank Repository (Salamanca) for supplying part of the control samples. This study was supported by European Union FEDER funds and `Fondo de Investigaciones SanitariasÂŽ (Grant PI18/00042) from âInstituto de Salud Carlos IIIâ (ISCIII, Health Ministry, Spain). DP-P is a recipient of a RĂo Hortega programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, `Investing in your futureÂŽ) (Grant Number CM20/00006). SR-M is supported by funds of the RETICS Program (RD16/0012/0009) (ISCIII, cofunded by the European Regional Development Fund (ERDF)). VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL 18/01). BA-M is a recipient of a `LĂłpez AlboÂŽ Post-Residency Programme funded by Servicio CĂĄntabro de Salud. LL-G is supported by funds from IDIVAL (INNVAL20/06). OG is staff personnel of Xunta de Galicia (Servizo Galego de Saude (SERGAS)) through a research-staff stabilization contract (ISCIII/SERGAS) and his work is funded by ISCIII and the European Union FEDER fund (Grant Numbers RD16/0012/0014 (RIER) and PI17/00409). He is beneficiary of project funds from the Research Executive Agency (REA) of the European Union in the framework of MSCA-RISE Action of the H2020 Programme, project 734899âOlive-Net. RL-M is a recipient of a Miguel Servet type I programme fellowship from the ISCIII, co-funded by ESF (`Investing in your futureÂŽ) (Grant Number CP16/00033)
Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding
Despite high prevalence of iron deficiency anemia (IDA) in patients with acute or chronic gastrointestinal bleeding (GIB), IDA and iron deficiency (ID) are frequently untreated. Reasons may be misconceptions about the impact and diagnosis of IDA and the efficacy of new treatments. Addressing these misconceptions, this article summarizes current evidence for better understanding and management of GIB-associated IDA. Despite only few controlled studies evaluated the efficacy of iron treatment in patients with GIB, there is consistent evidence suggesting that: (a) IDA should be diligently investigated, (b) effective treatment of ID/IDA improves outcomes such as health-related quality of life and can avoid severe cardiovascular consequences, and (c) intravenous iron should be considered as well-tolerated treatment in this setting. Overall, the misconceptions and practices outlined in this article should be replaced with strategies that are more in line with current guidelines and best practice in GIB and other underlying conditions of ID/IDA.A pesar de la alta prevalencia de anemia por dĂ©ficit de hierro (ADH) en pacientes con hemorragia digestiva (HD) aguda o crĂłnica, la ADH y el dĂ©ficit de hierro (DH) son frecuentemente infratratados. Diversos conceptos errĂłneos sobre el impacto, el diagnĂłstico y la eficacia de los nuevos tratamientos de la ADH probablemente lo justifican. Para abordar estos errores conceptuales, este artĂculo resume la evidencia actual para una mejor comprensiĂłn y manejo de la ADH. A pesar de que existen pocos estudios controlados que hayan evaluado la eficacia del tratamiento con hierro en pacientes con HD, hay evidencia que sugiere que: (a) la ADH debe ser investigada diligentemente; (b) el tratamiento eficaz del DH/ADH mejora la calidad de vida relacionada con la salud y puede evitar relevantes complicaciones cardiovasculares, y (c) el hierro intravenoso debe ser considerado como un tratamiento bien tolerado en este contexto. En general, los conceptos errĂłneos y las prĂĄcticas inadecuadas descritas en este artĂculo deben ser reemplazados por estrategias que estĂ©n mĂĄs en lĂnea con las directrices actuales y buenas prĂĄcticas clĂnicas en HD y otras condiciones causantes del DH/ADHinfo:eu-repo/semantics/publishedVersio
Seguridad de los inhibidores de la bomba de protones (IBP) Security of proton pump inhibitors
Treating Helicobacter pylori infection: small remedies for great evils? Tratamiento de la infección por Helicobacter pylori: ¿pequeños remedios para grandes males?
- âŠ